Glizid-M OD 60 Tablet SR is a combination oral antidiabetic medication containing Gliclazide 60 mg and Metformin 500 mg, formulated for sustained release to provide effective glycemic control in patients with type 2 diabetes mellitus. Gliclazide, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The sustained-release formulation allows for once-daily dosing, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with metformin. Glizid-M OD 60 is indicated as adjunctive therapy to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or lifestyle modifications alone. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia and lactic acidosis is essential during therapy. Dose adjustments may be necessary based on clinical response and tolerability. This combination offers a complementary mechanism of action, making it a valuable option in the management of type 2 diabetes.